Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

Pulmonary toxicity with mefloquine

E. Udry, F. Bailly, M. Dusmet, P. Schnyder, R. Lemoine, J.W. Fitting
European Respiratory Journal 2001 18: 890-892; DOI:
E. Udry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Bailly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Dusmet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Schnyder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Lemoine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.W. Fitting
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy. Extensive microbiological investigation remained negative and video-assisted thoracoscopic lung biopsy demonstrated diffuse alveolar damage. The evolution was favourable without treatment.

This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine. Glucose-;6-;phosphate dehydrogenase deficiency was present in the former case and was thought to contribute to the lung injury. However, glucose-phosphate dehydrogenase was normal in the present case, suggesting that it is not a predisposing condition to the lung injury.

  • acute lung injury
  • antimalarial drugs
  • diffuse alveolar damage
  • mefloquine

Mefloquine is used as prophylaxis or treatment for malaria in areas where chloroquine-resistant malaria is present. Although considered a relatively safe agent, its side-effects include neuropsychiatric reactions, cutaneous lesions, bone marrow toxicity, and gastrointestinal symptoms. Here, the authors report a case of pulmonary toxicity following mefloquine administration.

Case report

A 53-yr-old geologist returned to Switzerland from New Guinea after working there for 6 weeks in the countryside. He had a previous history of one episode of malaria, hepatitis A, and renal tuberculosis treated with adequate therapy. His recent health had been good until the present episode.

Eight days after his arrival in Switzerland, he developed a high fever and, suspecting malaria, started himself on halofantrine 500 mg q.i.d. for 48 h together with paracetamol. The fever stopped, but reappeared 1 week later with spikes every 48 h. Nineteen days after the first febrile episode, he went to an emergency department where the diagnosis of malaria with Plasmodium falciparum was established with a parasitaemia of 0.2%. He received a total dose of 1,500 mg mefloquine over 24 h. During the next night he had fever, cough and moderate dyspnoea and was then admitted to the hospital.

On admission, the patient was in poor general condition: thin, blood pressure 90/50 mmHg, heart rate 80 min−1, tympanic temperature 38°C, and respiratory rate 20 min−1. On examination, lung auscultation revealed fine crackles laterally on the left. Laboratory findings showed a low haemoglobin level (1.04 g·L−1), a haematocrit of 30%, and a leukocyte count of 15×109 L−1 with left deviation (63% segmented neutrophils, 10% nonsegmented neutrophils and 20% lymphocytes). C-;reactive protein was 188 mg·L−1 and lactic dehydrogenase 878 U·L−1. Hepatic and renal function tests were within normal limits. P. falciparum trophozoites were found in 0.1% of erythrocytes. The chest radiograph showed a slight infiltrate in the mid-field of the left lung.

The diagnosis was that P. falciparum malaria was persistent despite halofantrine treatment. The patient received one loading dose of parenteral quinine (20 mg·kg−1) then 10 mg·kg−1 q.i.d., followed by peroral quinine sulphate 650 mg t.i.d. for 5 days and doxycycline 100 mg b.i.d. for 5 days. Because of diarrhoea, ceftriaxone 2 g·day−1 was empirically added.

Two days later, the patient's condition deteriorated; he was dyspnoeic at rest and bilateral radiological pulmonary infiltrates increased markedly (fig. 1⇓). The arterial blood gases revealed severe hypoxaemia (oxygen tension in arterial blood (Pa,O2) 6.3 kPa (47 mmHg), carbon dioxide tension in arterial blood (Pa,CO2) 4.4 kPa (33 mmHg), pH 7.45, bicarbonate 23 mM). Because of a positive screening test (enzyme-linked immunosorbent assay (ELISA)+) for human immunodeficiency virus (HIV), Pneumocystis carinii pneumonia was suspected and a bronchoscopy with bronchoalveolar lavage (BAL) was performed. Tracheobronchial mucosa appeared normal and without secretions. BAL fluid showed an increased number of cells (82×106·L−1), with 43% neutrophils, 38.5% alveolar macrophages, 14.5% lymphocytes, 1.5% nonsegmented neutrophils, 1% eosinophils, and 1% basophils. Trimethoprim-sulfamethoxazole was started empirically after bronchoscopy, but was stopped after 48 h because P. carinii were absent in the BAL and the Western blot for HIV was negative. The patient's condition continued to deteriorate with increasing tachypnoea, arterial desaturation and increasing pulmonary infiltrate. Computed tomography (CT) confirmed the presence of diffuse bilateral pulmonary infiltrates of ground-glass attenuation and mild thickening of interlobular septa (fig. 2⇓). At that time, all microbiological investigations remained negative in the sputum (direct exam and culture for bacteria, fungi, mycobacteria, polymerase chain reaction (PCR) for Legionella), blood (cultures, serology for toxoplasmosis and Borrelia, buffy coat for cytomegalovirus, antigen for Cryptoccocus), urine (bacteria culture, antigen for Legionella), stool (enteroparasites, pathogenic bacteria, viruses), and BAL fluid (direct exam and culture for bacteria, fungi, mycobacteria, Legionella). Seven days after admission, a video-assisted thoracoscopic lung biopsy was performed, which showed hyaline membranes lining the alveolar spaces with sloughed type-;2 pneumocytes and a discrete interstitial thickening with lymphocytic infiltrates, consistent with diffuse alveolar damage (DAD) (fig. 3⇓). Lung biopsy and pleural fluid did not show any bacteria or fungi at histology or culture, viruses at culture, parasites at histology or toxoplasmosis by PCR.

Fig. 1.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.—

Posteroanterior chest radiograph showing diffuse confluent infiltrates.

Fig. 2.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.—

Chest computed tomography showing diffuse ground-glass pulmonary infiltrates and mild thickening of the interlobular septa.

Fig. 3.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.—

Histology of lung biopsy. The surface of the alveolar walls is lined by abundant fibrin deposits, with the typical aspect of hyaline membranes; the histological picture corresponds to that of diffuse alveolar damage (Internal scale bar=70 µm; haematoxylin and eosin)

Without further treatment, the patient's clinical condition gradually improved with regression of the radiological infiltrates. Twelve days after admission, he was able to perform lung function tests which showed a forced vital capacity (FVC) of 3.45 L (79% of predicted) and a carbon monoxide diffusing capacity of the lung (DL,CO) of 3.8 mmol·kPa−1·min−1 (40% pred). Arterial blood gases had also improved: Pa,O2 8.5 kPa (64 mmHg), Pa,CO2 4.5 kPa (34 mmHg), pH 7.46, bicarbonate 24 mmol·L−1. One month later, the patient was again in good condition, with only a minimal residual pulmonary infiltrate. The FVC was normal (106% pred), whereas DL,CO was still subnormal (60% pred). Two months later the radiological pulmonary infiltrates disappeared completely, whereas the DL,CO remained 64% pred.

Discussion

This patient developed rapidly, evolving diffuse lung infiltrates and hypoxaemia (Pa,O2/inspiratory oxygen fraction (FI,O2)=233) corresponding to an acute lung injury according to the criteria of the American-European Consensus Conference on acute respiratory distress syndrome (ARDS) (Pa,O2/FI,O2 <300, bilateral opacities compatible with pulmonary oedema, and pulmonary artery occlusion pressure <18 mmHg or no clinical evidence of left atrial hypertension) 1. The histopathological picture was consistent with DAD, thus opening a large differential diagnosis 2.

An infectious origin other than malaria could not be documented, as extensive microbiological investigations remained negative. Furthermore, the histological picture showed neither neutrophilic infiltrates or viral inclusions. Acute lung injury can occur secondary to malaria, but typically, only in the more severe forms of the disease, reflected by high acute physiological scores 4–7. The patient had only a low parasitaemia, which disappeared on the second day of hospital admission. Furthermore, he did not present any of the criteria of severe malaria, such as cerebral malaria with coma or seizures, severe anaemia, oliguric renal failure, hypoglycaemia, malignant hyperthermia, acidaemia or acidosis, circulatory collapse or shock, spontaneous bleeding, disseminated intravascular coagulation, or jaundice 8. Acute lung injury in malaria is also usually associated with a longer time interval to the initiation of adequate antimalarial therapy 10. Finally, the histological picture did not show any extravascular red blood cells, parasites within red blood cells or neutrophilic infiltrates. Thus, acute lung injury in this patient could not be considered to result from malaria.

On the basis of history and clinical examination there was no clue suggesting a toxic origin (such as one caused by smoke, paraquat, ethylchlorvynol, or illicit drugs), prior radiotherapy, collagen vascular disorders, or the other usual causes of ARDS. The Hamman-Rich syndrome could be ruled out by the spontaneously favourable evolution. A drug-induced origin remained the most likely hypothesis. Among the different medications the patient took before admission (halofantrine, paracetamol, mefloquine) and in the hospital (quinine, doxycycline and ceftriaxone), the only ones showing a clear time relation with the respiratory symptoms were mefloquine and paracetamol.

Recently, Drent 11 described a case of drug-induced pneumonia due to mefloquine in a patient with latent hemizygote glucose-phosphate dehydrogenase deficiency. The patient became dyspnoeic and febrile 2 days after taking mefloquine. Chest radiograph showed diffuse nonspecific interstitial infiltrates and lung CT showed diffuse opacities of ground-glass attenuation. All cultures remained sterile and transbronchial lung biopsy revealed DAD. The patient was treated with systemic corticosteroids (initially prednisone, 50 mg daily) and recovered completely. This patient was reported to present hemizygote deficiency of glucose-phosphate dehydrogenase. The author hypothesized that the severe lung injury resulted from a failure to induce glutathione redox cycle enzyme and from oxidative stress 11. The quantitative dosage of glucose-;6-;phosphate dehydrogenase was normal in the present authors' patient, suggesting that the finding of glucose-;6-;phosphate dehydrogenase deficiency in the case report of Drent 11 could be incidental. The present authors declined to rechallenge their patient by mefloquine.

In summary, this acute lung injury with diffuse alveolar damage was attributed to mefloquine, after ruling out all other possible causes. In view of the similarity between this case and the recent one reported by Drent 11, the authors recommend that mefloquine should be added to the list of drugs that are potentially harmful to the lungs.

  • Received January 29, 2001.
  • Accepted April 25, 2001.
  • © ERS Journals Ltd

References

  1. ↵
    Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818–824.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Katzenstein ALA, Bloor CM, Leibow M. Diffuse alveolar damage. The role of oxygen, shock, and related factors. Am J Pathol 1976;85:210–226.
    OpenUrlWeb of Science
  3. Blennerhassett JB. Shock lung and diffuse alveolar damage pathological and pathogenetic considerations. Pathology 1985;17:239–247.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Horstmann RD, Ehrich JHH, Beck J, Dietrich M. Letale Komplikationen der Malaria tropica bei Nichtimmunen. Dtsch Med Wschr 1985;110:1651–1656.
    OpenUrlPubMed
  5. Rioult B, Merit JB, Varache N, Trichet M. Oedème pulmonaire lésionnel d'évolution mortelle au cours d'un accès pernicieux palustre. Ann Fr Anesth Réanim 1990;9:557–559.
    OpenUrlPubMedWeb of Science
  6. Torres JR, Perez H, Postigo MM, Silva JR. Acute non cardiogenic lung injury in benign tertian malaria. Lancet 1997;350:31–32.
    OpenUrlPubMedWeb of Science
  7. ↵
    Aursudkij B, Wilairatana P, Vannaphan S, Walsh DS, Gordeux VR, Looareesuwan S. Pulmonary edema in cerebral malaria patients in Thailand. Southeast Asian J Trop Med Public Health 1998;29:541–545.
    OpenUrlPubMed
  8. ↵
    World Health Organization. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990;84:1–65.
    OpenUrlFREE Full Text
  9. Patel V, Khan FA. Pulmonary complications of malaria. Sem Respir Med 1991;12:8–17.
    OpenUrlCrossRef
  10. ↵
    Gachot B, Wolff M, Nissack G, Veber B, Vachon F. Acute lung injury complicating imported Plasmodium falciparum malaria. Chest 1995;108:746–749.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Drent M. Drug-induced pneumonia associated with hemizygote glucose-;6 phosphate-dehydrogenase deficiency. Eur J Haematol 1998;61:218–220.
    OpenUrlPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 18 Issue 5 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary toxicity with mefloquine
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary toxicity with mefloquine
E. Udry, F. Bailly, M. Dusmet, P. Schnyder, R. Lemoine, J.W. Fitting
European Respiratory Journal Nov 2001, 18 (5) 890-892;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary toxicity with mefloquine
E. Udry, F. Bailly, M. Dusmet, P. Schnyder, R. Lemoine, J.W. Fitting
European Respiratory Journal Nov 2001, 18 (5) 890-892;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Case report
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endobronchial pseudo-tumour caused by herpes simplex
  • Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease
  • Metabisulphite-induced occupational asthma in a radiographer
Show more Case Studies

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society